← Browse by Condition
Medical Condition

multiple system atrophy msa

Total Trials
3
Recruiting Now
3
Trial Phases
EARLY_Phase 1, Phase 1

ClinicalMetric tracks all active clinical trials for multiple system atrophy msa sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — multiple system atrophy msa Clinical Trials

How many clinical trials are currently recruiting for multiple system atrophy msa?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for multiple system atrophy msa, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for multiple system atrophy msa?
multiple system atrophy msa research spans Phase 1 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a multiple system atrophy msa clinical trial?
Eligibility criteria for multiple system atrophy msa trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Top Sponsors
AC Immune SA 1 trial
Beijing Tiantan Hospital 1 trial
Synusight Biotech (Shanghai) Co., Ltd. 1 trial

Recruiting Clinical Trials

NCT06891703 EARLY_Phase 1
Recruiting
[18F]ACI-15916 PET in α-synucleinopathies
Enrollment
46 pts
Location
Sweden
Sponsor
AC Immune SA
View Trial →
NCT06765733 EARLY_Phase 1
Recruiting
The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy
Enrollment
20 pts
Location
China
Sponsor
Beijing Tiantan Hospital
View Trial →
NCT07604116 Phase 1
Recruiting
A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA
Enrollment
30 pts
Location
China
Sponsor
Synusight Biotech (Shanghai) C...
View Trial →

Related Conditions

parkinson s disease pd (2) dementia with lewy bodies dlb (1) multiple system atrophy parkinsonian subtype msa p (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology